Company Overview
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom Real-Time API, which enables invited third-party developers to integrate real-time CGM data into their digital health applications and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Dexcom Share, a remote monitoring system. The company's products candidature comprises Dexcom G7, a next generation G7 CGM system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was incorporated in 1999 and is headquartered in San Diego, California.
Company Information
- CEO
- Kevin Ronald Sayer
- Sector
- Healthcare
- Industry
- Medical - Devices
- Employees
- 10200
Contact Information
- Website
- https://www.dexcom.com
- Address
- 6340 Sequence Drive
- Country
- US
Investment Analysis & Insights
Key Investment Highlights
- Market Position: Healthcare leader with 30.93B market capitalization
- Trading Volume: 3.82M shares traded today
- Price Range: 52-week range of $57.52 - $93.25
- Exchange: Listed on NASDAQ Global Select
Financial Metrics
Market Analysis for DexCom, Inc.
DexCom, Inc. (DXCM) operates in the Medical - Devices industry within the Healthcare sector. With a current market capitalization of 30.93B, the company represents a significant player in its market. The stock is currently trading at $78.86 with a positivedaily change of 3.22%.
The company's 10200 employee base and presence on the NASDAQ Global Selectexchange position it as a Healthcare sector leader. Investors should consider the stock's P/E ratio of 55.54, beta of 1.44, and 52-week price range from $57.52 to $93.25when evaluating investment opportunities.
Why Invest in DexCom, Inc.?
Strengths
- • Established market presence in Healthcare
- • Strong financial metrics and market position
- • Listed on major exchange (NASDAQ Global Select)
- • Experienced leadership under Kevin Ronald Sayer
Investment Considerations
- • Monitor sector-specific market trends
- • Track quarterly earnings performance
- • Consider market volatility and beta
- • Evaluate long-term growth potential
Related Healthcare Stocks
About Healthcare Sector
The Healthcare sector includes companies that provide medical services, develop pharmaceuticals, manufacture medical devices, and offer health insurance.